FindTrial
Sign In

Olmesartan Mega study to determine the relationship between Cardiovascular Endpoints and Blood pressure Goal Achievement

Olmesartan Mega study to determine the relationship between Cardiovascular Endpoints and Blood pressure Goal Achievement

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080220002
Enrollment
Unknown
Registered
2005-07-29
Start date
2005-07-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

investigational material(s) Generic name etc : Olmetec(Olmesartan Medoxomil) INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investig

Sponsors

DAIICHI SANKYO COMPANY, LIMITED
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Essential hypertension, outpatient, consenting patient, age 50-79.

Exclusion criteria

Exclusion criteria: A history of myocardial infarction, stroke, coronary artery bypass graft surgery, and percutaneous coronary intervention within 6 months before the registration.A scheduled coronary intervention at registration. A diagnosis congenital or rheumatic heart disease, severe arrhythmia, liver or renal disease, and current diagnosis of malignancy.

Design outcomes

Primary

MeasureTime frame
Development of stroke,myocardial infarction, unstable angina required hospitalization,and sudden and unexpected death.—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026